Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2 Recruiting 45 enrolled Sichuan University

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) combined with sugemalimab, olaparib, chemotherapy in the first-line treatment of SLFN-11 positive extensive stage small cell lung cancer.

Timeline

Start: 2024-04-18
Primary completion: 2027-10-31
Completion: 2028-10-31

Publications

Kaczorowski M, Ylaya K, Chlopek M, Taniyama D, Pommier Y, Lasota J, Miettinen M. Immunohistochemical Evaluation of Schlafen 11 (SLFN11) Expression in Cancer in the Search of Biomarker-Informed Treatment Targets: A Study of 127 Entities Represented by 6658 Tumors. Am J Surg Pathol. 2024 Dec 1;48(12):1512-1521. doi: 10.1097/PAS.0000000000002299. Epub 2024 Aug 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olaparib	Small molecule	150 mg	Oral
Subject	Olaparib	Small molecule	300 mg	Oral
Background	Cisplatin	Other / unclassified	25 mg/m2	Intravenous
Background	Etoposide	Small molecule	100 mg/m2	Intravenous
Background	Sugemalimab	Monoclonal antibody	1200 mg	Intravenous

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Summary

Timeline

Publications

Drugs

Indications